BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 23944298)

  • 1. Long-term survival of participants in the prostate cancer prevention trial.
    Thompson IM; Goodman PJ; Tangen CM; Parnes HL; Minasian LM; Godley PA; Lucia MS; Ford LG
    N Engl J Med; 2013 Aug; 369(7):603-10. PubMed ID: 23944298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.
    Redman MW; Tangen CM; Goodman PJ; Lucia MS; Coltman CA; Thompson IM
    Cancer Prev Res (Phila); 2008 Aug; 1(3):174-81. PubMed ID: 19138953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
    Unger JM; Till C; Thompson IM; Tangen CM; Goodman PJ; Wright JD; Barlow WE; Ramsey SD; Minasian LM; Hershman DL
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27565902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride.
    Dai JY; LeBlanc M; Goodman PJ; Lucia MS; Thompson IM; Tangen CM
    Cancer Prev Res (Phila); 2019 Feb; 12(2):113-120. PubMed ID: 30538099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with finasteride and prostate cancer survival.
    Kjellman A; Friis S; Granath F; Gustafsson O; Sørensen HT; Akre O
    Scand J Urol; 2013 Aug; 47(4):265-71. PubMed ID: 23137166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.
    Chu LW; Till C; Yang B; Tangen CM; Goodman PJ; Yu K; Zhu Y; Han S; Hoque AM; Ambrosone C; Thompson I; Leach R; Hsing AW
    Mol Carcinog; 2018 Mar; 57(3):462-466. PubMed ID: 29318656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
    Lucia MS; Epstein JI; Goodman PJ; Darke AK; Reuter VE; Civantos F; Tangen CM; Parnes HL; Lippman SM; La Rosa FG; Kattan MW; Crawford ED; Ford LG; Coltman CA; Thompson IM
    J Natl Cancer Inst; 2007 Sep; 99(18):1375-83. PubMed ID: 17848673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
    Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
    Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of finasteride on the development of prostate cancer.
    Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
    N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
    Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
    Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
    Unger JM; Hershman DL; Till C; Tangen CM; Barlow WE; Ramsey SD; Goodman PJ; Thompson IM
    J Natl Cancer Inst; 2018 Nov; 110(11):1208-1215. PubMed ID: 29534197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-alpha-reductase Inhibitors for prostate cancer prevention.
    Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
    Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.
    Hoque A; Yao S; Till C; Kristal AR; Goodman PJ; Hsing AW; Tangen CM; Platz EA; Stanczyk FZ; Reichardt JK; vanBokhoven A; Neuhouser ML; Santella RM; Figg WD; Price DK; Parnes HL; Lippman SM; Ambrosone CB; Thompson IM
    Urology; 2015 Mar; 85(3):616-20. PubMed ID: 25733274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
    Lucia MS; Darke AK; Goodman PJ; La Rosa FG; Parnes HL; Ford LG; Coltman CA; Thompson IM
    Cancer Prev Res (Phila); 2008 Aug; 1(3):167-73. PubMed ID: 19138952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.
    Pinsky PF; Black A; Grubb R; Crawford ED; Andriole G; Thompson I; Parnes H
    Cancer; 2013 Feb; 119(3):593-601. PubMed ID: 22893105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.
    Liang Y; Ketchum NS; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
    Urol Int; 2012; 89(1):9-16. PubMed ID: 22626812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.
    Murtola TJ; Gurel B; Umbehr M; Lucia MS; Thompson IM; Goodman PJ; Kristal AR; Parnes HL; Lippman SM; Sutcliffe S; Peskoe SB; Barber JR; Drake CG; Nelson WG; De Marzo AM; Platz EA
    Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):463-9. PubMed ID: 26715424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.